IL160557A0 - Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain - Google Patents

Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain

Info

Publication number
IL160557A0
IL160557A0 IL16055702A IL16055702A IL160557A0 IL 160557 A0 IL160557 A0 IL 160557A0 IL 16055702 A IL16055702 A IL 16055702A IL 16055702 A IL16055702 A IL 16055702A IL 160557 A0 IL160557 A0 IL 160557A0
Authority
IL
Israel
Prior art keywords
parkinson
brain
compositions
treatment
product
Prior art date
Application number
IL16055702A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL160557A0 publication Critical patent/IL160557A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16055702A 2001-08-29 2002-08-28 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain IL160557A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0111200A FR2829028B1 (fr) 2001-08-29 2001-08-29 Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
PCT/FR2002/002946 WO2003020314A1 (fr) 2001-08-29 2002-08-28 Compositions pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau

Publications (1)

Publication Number Publication Date
IL160557A0 true IL160557A0 (en) 2004-07-25

Family

ID=8866792

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16055702A IL160557A0 (en) 2001-08-29 2002-08-28 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
IL193325A IL193325A0 (en) 2001-08-29 2008-08-07 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL193325A IL193325A0 (en) 2001-08-29 2008-08-07 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain

Country Status (16)

Country Link
US (2) US7217705B2 (xx)
EP (2) EP1649849A3 (xx)
JP (2) JP2005505551A (xx)
AR (1) AR036302A1 (xx)
AT (1) ATE328609T1 (xx)
AU (2) AU2002337277B2 (xx)
CA (1) CA2458348A1 (xx)
CY (1) CY1105341T1 (xx)
DE (1) DE60212148T2 (xx)
DK (1) DK1423145T3 (xx)
ES (1) ES2263816T3 (xx)
FR (1) FR2829028B1 (xx)
IL (2) IL160557A0 (xx)
MX (1) MXPA04001645A (xx)
PT (1) PT1423145E (xx)
WO (1) WO2003020314A1 (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
RU2006133258A (ru) * 2004-02-17 2008-04-10 Лабораториос Дель Др. Эстеве С.А. (Es) Замещенные азетидиновые производные, их получение и применение в качестве лекарственных средств
ES2244314B1 (es) * 2004-02-17 2007-02-01 Laboratorios Del Dr. Esteve, S.A. Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos.
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
CA2613235A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
PT2114933E (pt) 2007-01-04 2011-12-20 Prosidion Ltd Agonistas do gpcr de piperidina
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
MX2010005925A (es) * 2007-11-28 2010-08-02 Ucb Pharma Gmbh Nueva forma polimorfico de rotigotina y proceso para la produccion.
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CN102459240A (zh) 2009-04-22 2012-05-16 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的氮杂环丁烷基二酰胺
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EA025584B1 (ru) 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
RU2013123274A (ru) 2010-10-22 2014-11-27 Янссен Фармацевтика Нв Аминопирролидиназетидиндиамиды как ингибиторы моноацилглицеринлипазы
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
WO2022245900A2 (en) * 2021-05-21 2022-11-24 Murphy Brian Stuart Compositions for treating inflammatory, neurologic and/or vascular conditions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
US20030078189A1 (en) * 1999-12-10 2003-04-24 Yohko Akiyama Medicinal compositions for oral use
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation

Also Published As

Publication number Publication date
CA2458348A1 (en) 2003-03-13
CY1105341T1 (el) 2010-03-03
US20040209861A1 (en) 2004-10-21
EP1649849A2 (fr) 2006-04-26
US20070197654A1 (en) 2007-08-23
US7217705B2 (en) 2007-05-15
EP1423145A1 (fr) 2004-06-02
PT1423145E (pt) 2006-09-29
ATE328609T1 (de) 2006-06-15
JP2010053153A (ja) 2010-03-11
EP1649849A3 (fr) 2006-11-02
DK1423145T3 (da) 2006-10-02
JP2005505551A (ja) 2005-02-24
AR036302A1 (es) 2004-08-25
MXPA04001645A (es) 2004-05-31
EP1423145B1 (fr) 2006-06-07
WO2003020314A1 (fr) 2003-03-13
IL193325A0 (en) 2009-02-11
AU2002337277B2 (en) 2008-06-05
ES2263816T3 (es) 2006-12-16
AU2008212039A1 (en) 2008-10-09
FR2829028B1 (fr) 2004-12-17
FR2829028A1 (fr) 2003-03-07
DE60212148T2 (de) 2007-04-19
DE60212148D1 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
IL193325A0 (en) Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
AU2002337277A1 (en) Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
IL160558A0 (en) Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
HUP0103654A2 (hu) Szmilagenin és/vagy anzurogenin-D alkalmazása Alzheimer-kór kezelésére szolgáló gyógyszerkészítmény előállítására
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
HUP0103558A3 (en) Pharmaceutical composition containing nmda receptor antagonist for the treatment of stroke and traumatic brain insury
GB0400167D0 (en) Dopaminergic neurons and proliferation-competent orecursor cells for treating parkinson's disease
HUP0302956A3 (en) Thioflavin derivatives for use in diagnosis of alzheimer's disease, process for preparation of compounds and pharmaceutical compositions containing them
SI1303272T1 (sl) Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni
IL188506A0 (en) Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease
HUP0303037A3 (en) Compounds to treat alzheimer's disease and pharmaceutical compositions containing them
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
HUP0402026A3 (en) 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them
EP1827468A4 (en) LEUPROLID ACETATE AND ACETYLCHOLINESTERASE INHIBITORS OR NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALZHEIMER DISEASE
MX9801305A (es) Composicion de disolucion rapida oral para agonistas de dopamina.
IL163102A (en) Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
IL112895A (en) Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists
HK1046405A1 (zh) 作為nmda受體拮抗劑用於治療疼痛的取代的1,5-二氫吡咯-2-酮衍生物
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
IL172213A0 (en) Compounds useful in the therapy of alzheimer's disease and formulations containing them
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
HUP0102987A3 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient